LIST OF TABLES
TABLE 01. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 02. OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 03. OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2021-2031 ($MILLION)
TABLE 05. OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 07. OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
TABLE 08. OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
TABLE 09. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 10. OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 11. OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 12. OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 19. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 20. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 21. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 22. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 23. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 26. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 27. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 29. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 32. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 33. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 36. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 39. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 42. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 45. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 53. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 54. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 55. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 57. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 58. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 60. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 61. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 64. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 65. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 66. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 67. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 72. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 73. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 74. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 75. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 77. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 80. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. ABBVIE INC.: KEY EXECUTIVES
TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 91. ABBVIE INC.: KEY STRATERGIES
TABLE 92. ALEMBIC PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 93. ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 94. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 95. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 96. ALEMBIC PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 97. ASTELLAS PHARMA INC.: KEY EXECUTIVES
TABLE 98. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 99. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
TABLE 100. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 101. ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 102. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
TABLE 103. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 104. DR. REDDY’S LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 105. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 106. DR. REDDY’S LABORATORIES LTD.: KEY STRATERGIES
TABLE 107. PFIZER INC.: KEY EXECUTIVES
TABLE 108. PFIZER INC.: COMPANY SNAPSHOT
TABLE 109. PFIZER INC.: PRODUCT SEGMENTS
TABLE 110. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 111. SUMITOMO PHARMA CO., LTD: KEY EXECUTIVES
TABLE 112. SUMITOMO PHARMA CO., LTD: COMPANY SNAPSHOT
TABLE 113. SUMITOMO PHARMA CO., LTD: PRODUCT SEGMENTS
TABLE 114. SUMITOMO PHARMA CO., LTD: PRODUCT PORTFOLIO
TABLE 115. SUMITOMO PHARMA CO., LTD: KEY STRATERGIES
TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 121. CIPLA LTD: KEY EXECUTIVES
TABLE 122. CIPLA LTD: COMPANY SNAPSHOT
TABLE 123. CIPLA LTD: PRODUCT SEGMENTS
TABLE 124. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 125. LUPIN: KEY EXECUTIVES
TABLE 126. LUPIN: COMPANY SNAPSHOT
TABLE 127. LUPIN: PRODUCT SEGMENTS
TABLE 128. LUPIN: PRODUCT PORTFOLIO
TABLE 129. LUPIN: KEY STRATERGIES
TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 132. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 133. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO LIST OF FIGURES
FIGURE 01. OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN OVERACTIVE BLADDER TREATMENT MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALOVERACTIVE BLADDER TREATMENT MARKET
FIGURE 10. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY COUNTRY 2021-2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY COUNTRY 2021-2031(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY COUNTRY 2021-2031(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
FIGURE 15. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY COUNTRY 2021-2031(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY COUNTRY 2021-2031(%)
FIGURE 18. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
FIGURE 22. OVERACTIVE BLADDER TREATMENT MARKET BY REGION, 2021
FIGURE 23. U.S. OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 24. CANADA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 26. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 27. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 28. UK OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 29. ITALY OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 30. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 31. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 32. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 33. CHINA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 34. INDIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 35. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 36. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 38. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 39. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 40. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 41. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2021
FIGURE 49. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 50. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 51. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 52. ALEMBIC PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 53. ASTELLAS PHARMA INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 54. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 55. DR. REDDY’S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 56. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 57. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 58. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 61. SUMITOMO PHARMA CO., LTD: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 62. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 63. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 66. CIPLA LTD: SALES REVENUE, 2019-2021 ($MILLION)
FIGURE 67. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 68. CIPLA LTD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 69. LUPIN: NET SALES, 2019-2021 ($MILLION)
FIGURE 70. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 72. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%